MGA’s Alex Brill on CNBC’s Squawk Box Discussing Tackling the Tax Gap
Alex Brill joined CNBC’s “Squawk Box” to discuss the IRS’ attempt to crack down on the tax gap.
Alex Brill on Single-Payer Health Care System and Drug Costs
Alex Brill is a senior fellow at the American Enterprise Institute (AEI), where he studies the impact of tax policy on the US economy as well as the fiscal, economic, and political consequences of tax, budget, health care, retirement security, and trade policies.
New MGA Analysis Finds Drug Rebates Not Associated with List Price Increases
In a new report, MGA examines the role of rebates among a subset of prescription drugs with the biggest price hikes between 2018 and 2023.
Alex Brill mentioned on MSN
If the Supreme Court rules in their favor, it could open the door to reshaping the country’s tax code.
Alex Brill Speaks on Consequences of Proposed PBM Constraints
In December, MGA CEO Alex Brill participated in a RealClearPolitics event looking at the negative consequences of limiting the business practices of PBMs.
- FDA Continues to Expedite Biosimilar Development
- Diminishing Returns from the Government’s Drug Negotiation Program
- Would Senate Passage of an ACA Tax Credit Extension Matter?
- MGA Brief Examines State and Federal PBM Mandates
- FDA Moves to Facilitate Biosimilar Development
- How Pharmaceutical Tariffs Will Affect US Health Care Costs
- MGA Releases New Report Quantifying the Economic Impact of Healthcare Distributors
- The Unsung Hero of the OBBBA: Permanent Expensing
- Alex Brill Interviewed by Biosimilars Review & Report
- MGA Releases New White Paper on Medicare Price Negotiations and Drug Competition
